US6727230B1
(en)
*
|
1994-03-25 |
2004-04-27 |
Coley Pharmaceutical Group, Inc. |
Immune stimulation by phosphorothioate oligonucleotide analogs
|
US20030026782A1
(en)
*
|
1995-02-07 |
2003-02-06 |
Arthur M. Krieg |
Immunomodulatory oligonucleotides
|
US6239116B1
(en)
*
|
1994-07-15 |
2001-05-29 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
US6429199B1
(en)
*
|
1994-07-15 |
2002-08-06 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules for activating dendritic cells
|
US6207646B1
(en)
*
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
US7935675B1
(en)
|
1994-07-15 |
2011-05-03 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
EP0879284B1
(de)
*
|
1996-01-30 |
2009-07-29 |
The Regents of The University of California |
Expressionsvektoren, die eine antigen-spezifische immunantwort induzieren, und methoden für ihre verwendung.
|
EP0855184A1
(de)
*
|
1997-01-23 |
1998-07-29 |
Grayson B. Dr. Lipford |
Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
|
US6406705B1
(en)
*
|
1997-03-10 |
2002-06-18 |
University Of Iowa Research Foundation |
Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
|
US6274591B1
(en)
*
|
1997-11-03 |
2001-08-14 |
Joseph F. Foss |
Use of methylnaltrexone and related compounds
|
US20030158220A1
(en)
*
|
1997-11-03 |
2003-08-21 |
Foss Joseph F. |
Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
|
ES2284247T3
(es)
*
|
1998-04-03 |
2007-11-01 |
University Of Iowa Research Foundation |
Metodos y productos para estimular el sistema inmunitario usando oligonucleotidos y citoquinas inmunoterapeuticos.
|
IL139646A0
(en)
*
|
1998-05-14 |
2002-02-10 |
Coley Pharm Group Inc |
Methods for regulating hematopoiesis using cpg-oligonucleotides
|
EP1733735B1
(de)
*
|
1998-05-22 |
2017-03-22 |
Ottawa Hospital Research Institute |
Verfahren und Produkte zur Induktion von mukosaler Immunität
|
US20030022854A1
(en)
|
1998-06-25 |
2003-01-30 |
Dow Steven W. |
Vaccines using nucleic acid-lipid complexes
|
US6693086B1
(en)
*
|
1998-06-25 |
2004-02-17 |
National Jewish Medical And Research Center |
Systemic immune activation method using nucleic acid-lipid complexes
|
EP2204186B1
(de)
*
|
1999-02-17 |
2016-04-06 |
CSL Limited |
Immunogene Komplexe und damit zusammenhängende Verfahren
|
EP1176966B1
(de)
|
1999-04-12 |
2013-04-03 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Oligodeoxynukleotide und deren verwendung zur induktion einer immunreaktion
|
US6977245B2
(en)
|
1999-04-12 |
2005-12-20 |
The United States Of America As Represented By The Department Of Health And Human Services |
Oligodeoxynucleotide and its use to induce an immune response
|
WO2000067796A1
(en)
*
|
1999-05-07 |
2000-11-16 |
Genentech, Inc. |
Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
|
JP2003528805A
(ja)
*
|
1999-07-12 |
2003-09-30 |
ジェネンテック・インコーポレーテッド |
Cd20に結合するアンタゴニストを用いた異種抗原に対する免疫応答のブロッキング
|
AP1775A
(en)
*
|
1999-09-25 |
2007-08-28 |
Univ Iowa Res Found |
Immunostimulatory nucleic acids.
|
US6949520B1
(en)
*
|
1999-09-27 |
2005-09-27 |
Coley Pharmaceutical Group, Inc. |
Methods related to immunostimulatory nucleic acid-induced interferon
|
AU3108001A
(en)
*
|
2000-01-20 |
2001-12-24 |
Coley Pharmaceutical Group, Inc. |
Immunostimulatory nucleic acids for inducing a th2 immune response
|
US7585847B2
(en)
*
|
2000-02-03 |
2009-09-08 |
Coley Pharmaceutical Group, Inc. |
Immunostimulatory nucleic acids for the treatment of asthma and allergy
|
DK1255558T3
(da)
*
|
2000-02-16 |
2006-10-23 |
Genentech Inc |
Anti-april antistoffer og hybridomaceller
|
US20040131628A1
(en)
*
|
2000-03-08 |
2004-07-08 |
Bratzler Robert L. |
Nucleic acids for the treatment of disorders associated with microorganisms
|
US7030219B2
(en)
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
EP1292331A2
(de)
*
|
2000-06-07 |
2003-03-19 |
Biosynexus Incorporated |
Immunstimulierende rns/dns hybridmolekule
|
KR100917101B1
(ko)
*
|
2000-08-04 |
2009-09-15 |
도요 보세키 가부시키가이샤 |
플렉시블 금속적층체 및 그 제조방법
|
WO2002022809A2
(en)
*
|
2000-09-15 |
2002-03-21 |
Coley Pharmaceutical Gmbh |
PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST
|
CA2422076A1
(en)
*
|
2000-09-18 |
2002-03-21 |
Idec Pharmaceutical Corporation |
Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
|
TWI283575B
(en)
*
|
2000-10-31 |
2007-07-11 |
Eisai Co Ltd |
Medicinal compositions for concomitant use as anticancer agent
|
EP1985702A3
(de)
*
|
2000-12-08 |
2010-08-18 |
Coley Pharmaceutical GmbH |
CPG-ähnliche Nukleinsäuren und Verwendungsverfahren dafür
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US7829084B2
(en)
*
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
US7666674B2
(en)
|
2001-07-27 |
2010-02-23 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
|
EP1501359A4
(de)
*
|
2001-08-03 |
2007-04-18 |
Celldex Therapeutics Inc |
Immunstimulierende oligonukleotide enthaltende zusammensetzungen sowie verwendungen davon zur verbesserung fc-rezeptor-vermittelter immuntherapien
|
WO2003014294A2
(en)
*
|
2001-08-03 |
2003-02-20 |
Genentech, Inc. |
Tacis and br3 polypeptides and uses thereof
|
AU2002361468A1
(en)
*
|
2001-08-14 |
2003-03-18 |
The Government Of The United States Of America As Represented By The Secretary Of Health And Human S |
Method for rapid generation of mature dendritic cells
|
SG177000A1
(en)
*
|
2001-08-17 |
2012-01-30 |
Coley Pharm Gmbh |
Combination motif immune stimulatory oligonucleotides with improved activity
|
CN1575184A
(zh)
*
|
2001-09-07 |
2005-02-02 |
波士顿大学理事会 |
治疗免疫复合物相关疾病的方法和组合物
|
BR0213097A
(pt)
*
|
2001-10-05 |
2005-02-01 |
Coley Pharm Gmbh |
Agonistas e antagonistas sinalizadores do receptor 3 similar a toll
|
US20030139364A1
(en)
*
|
2001-10-12 |
2003-07-24 |
University Of Iowa Research Foundation |
Methods and products for enhancing immune responses using imidazoquinoline compounds
|
US8466116B2
(en)
|
2001-12-20 |
2013-06-18 |
The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Use of CpG oligodeoxynucleotides to induce epithelial cell growth
|
AU2002366710A1
(en)
|
2001-12-20 |
2003-07-09 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of |
USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
|
US7741297B2
(en)
|
2002-02-04 |
2010-06-22 |
Oncothyreon Inc. |
Immunostimulatory, covalently lipidated oligonucleotides
|
US8088388B2
(en)
*
|
2002-02-14 |
2012-01-03 |
United Biomedical, Inc. |
Stabilized synthetic immunogen delivery system
|
EP3006043B1
(de)
|
2002-04-04 |
2019-05-29 |
Zoetis Belgium S.A. |
Immunostimulatorische g,u-haltige oligoribonucleotide
|
US7968569B2
(en)
*
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
US20040009949A1
(en)
*
|
2002-06-05 |
2004-01-15 |
Coley Pharmaceutical Group, Inc. |
Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids
|
JP5027387B2
(ja)
*
|
2002-07-01 |
2012-09-19 |
タフツ・ユニバーシティ |
ヒアルロナンオリゴマーにより多剤耐性を阻害する方法及び組成物
|
US7605138B2
(en)
*
|
2002-07-03 |
2009-10-20 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
US7569553B2
(en)
*
|
2002-07-03 |
2009-08-04 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
US7807803B2
(en)
*
|
2002-07-03 |
2010-10-05 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
US7576066B2
(en)
|
2002-07-03 |
2009-08-18 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
US20040053880A1
(en)
*
|
2002-07-03 |
2004-03-18 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
CA2492447A1
(en)
*
|
2002-07-25 |
2004-02-05 |
Genentech, Inc. |
Taci antibodies and uses thereof
|
SG166673A1
(en)
*
|
2002-08-19 |
2010-12-29 |
Coley Pharm Group Inc |
Immunostimulatory nucleic acids
|
AR040996A1
(es)
*
|
2002-08-19 |
2005-04-27 |
Coley Pharm Group Inc |
Acidos nucleicos inmunoestimuladores
|
FR2844455B1
(fr)
*
|
2002-09-13 |
2007-12-14 |
Lab Francais Du Fractionnement |
Traitement des pathologies echappant a la reponse immune par des anticorps optimises
|
US8263091B2
(en)
*
|
2002-09-18 |
2012-09-11 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
|
SI1558648T1
(sl)
|
2002-10-17 |
2012-05-31 |
Genmab As |
Človeška monoklonalna protitelesa proti CD
|
ZA200503511B
(en)
*
|
2002-10-29 |
2006-10-25 |
Coley Pharmaceutical Group Ltd |
Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
|
US7956043B2
(en)
|
2002-12-11 |
2011-06-07 |
Coley Pharmaceutical Group, Inc. |
5′ CpG nucleic acids and methods of use
|
DE60332957D1
(de)
*
|
2002-12-16 |
2010-07-22 |
Genentech Inc |
Immunoglobulinvarianten und deren verwendungen
|
US7470714B2
(en)
*
|
2003-03-04 |
2008-12-30 |
Sosei Co., Ltd. |
GM-95-containing antitumor effect potentiator, combined antitumor preparation and antitumor agent
|
AU2004226605A1
(en)
*
|
2003-04-02 |
2004-10-14 |
Coley Pharmaceutical Group, Ltd. |
Immunostimulatory nucleic acid oil-in-water formulations for topical application
|
AU2004229464A1
(en)
*
|
2003-04-08 |
2004-10-28 |
Progenics Pharmaceuticals, Inc. |
Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
|
CN104383542B
(zh)
|
2003-04-08 |
2017-09-26 |
普罗热尼奇制药公司 |
包含甲基纳曲酮的药物配方
|
US20050004155A1
(en)
*
|
2003-04-08 |
2005-01-06 |
Boyd Thomas A. |
Use of methylnaltrexone to treat irritable bowel syndrome
|
ES2322267T3
(es)
*
|
2003-04-09 |
2009-06-18 |
Genentech, Inc. |
Terapia de una enfermedad autoinmunologica en un paciente que presenta una respuesta inadecuada a un inhibidor de tnf-alfa.
|
MXPA05012421A
(es)
*
|
2003-05-16 |
2006-02-22 |
Hybridon Inc |
Tratamiento sinergistico de cancer usando inmunomeros junto con agentes quimioterapeuticos.
|
KR20060027801A
(ko)
*
|
2003-06-05 |
2006-03-28 |
제넨테크, 인크. |
B 세포 장애에 대한 조합 요법
|
US20050163775A1
(en)
*
|
2003-06-05 |
2005-07-28 |
Genentech, Inc. |
Combination therapy for B cell disorders
|
BRPI0411514A
(pt)
*
|
2003-06-20 |
2006-08-01 |
Coley Pharm Gmbh |
antagonistas de receptor toll-like de molécula pequena
|
US20050013812A1
(en)
*
|
2003-07-14 |
2005-01-20 |
Dow Steven W. |
Vaccines using pattern recognition receptor-ligand:lipid complexes
|
ZA200600798B
(en)
*
|
2003-07-29 |
2007-06-27 |
Genentech Inc |
Assay for human anti CD20 antibodies and uses therefor
|
MXPA06002134A
(es)
*
|
2003-08-29 |
2006-05-31 |
Genentech Inc |
Terapia de trastornos oculares.
|
AU2004275876B2
(en)
*
|
2003-09-25 |
2011-03-31 |
Coley Pharmaceutical Gmbh |
Nucleic acid-lipophilic conjugates
|
EP1675614A2
(de)
*
|
2003-10-11 |
2006-07-05 |
Inex Pharmaceuticals Corp. |
Verfahren und zusammensetzungen zur verbesserung der inhärenten immunität und antikörper-abhängigen zellulären zytotoxizität
|
CN101454451A
(zh)
*
|
2003-10-30 |
2009-06-10 |
科勒制药有限公司 |
具有增强免疫刺激能力的c类寡核苷酸类似物
|
US20050239733A1
(en)
*
|
2003-10-31 |
2005-10-27 |
Coley Pharmaceutical Gmbh |
Sequence requirements for inhibitory oligonucleotides
|
US20050100983A1
(en)
*
|
2003-11-06 |
2005-05-12 |
Coley Pharmaceutical Gmbh |
Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
|
US9050378B2
(en)
|
2003-12-10 |
2015-06-09 |
Board Of Regents, The University Of Texas System |
N2S2 chelate-targeting ligand conjugates
|
CA2550058C
(en)
*
|
2003-12-19 |
2016-07-12 |
Antisense Pharma Gmbh |
Pharmaceutical composition comprising a tgf-beta2 antisense oligonucleotide and a chemotherapeutic
|
EP1696955A2
(de)
*
|
2003-12-19 |
2006-09-06 |
Genentech, Inc. |
Nachweis von cd20 in der therapie von autoimmunkrankheiten
|
AU2004303848A1
(en)
*
|
2003-12-19 |
2005-07-07 |
Genentech, Inc. |
Detection of CD20 in transplant rejection
|
EP1720568A2
(de)
*
|
2004-02-19 |
2006-11-15 |
Coley Pharmaceutical Group, Inc. |
Immunstimulatorische virale rna-oligonucleotide
|
TWI235440B
(en)
*
|
2004-03-31 |
2005-07-01 |
Advanced Semiconductor Eng |
Method for making leadless semiconductor package
|
AU2005243250A1
(en)
*
|
2004-04-02 |
2005-11-24 |
Coley Pharmaceutical Gmbh |
Immunostimulatory nucleic acids for inducing IL-10 responses
|
EP1735000A2
(de)
*
|
2004-04-16 |
2006-12-27 |
Genentech, Inc. |
Verfahren zur verstärkung des b-zellabbaus
|
JP5848861B2
(ja)
|
2004-04-20 |
2016-01-27 |
ジェンマブ エー/エスGenmab A/S |
Cd20に対するヒトモノクローナル抗体
|
CN1980697A
(zh)
*
|
2004-05-05 |
2007-06-13 |
健泰科生物技术公司 |
通过使用抗cd20抗体预防自身免疫病
|
US7531628B2
(en)
*
|
2004-05-28 |
2009-05-12 |
Idexx Laboratories, Inc. |
Canine CD20 compositions
|
US20060051345A1
(en)
*
|
2004-06-04 |
2006-03-09 |
Genentech, Inc. |
Method for treating multiple sclerosis
|
AR049292A1
(es)
*
|
2004-06-04 |
2006-07-12 |
Genentech Inc |
Metodo para tratar lupus con un anticuerpo cd20
|
EP2484374A1
(de)
*
|
2004-07-18 |
2012-08-08 |
CSL Limited |
Immunstimulierender Komplex und Oligonucleotidformulierungen zur Induzierung verbesserter Interferon-Gamma-Antworten
|
BRPI0513100A
(pt)
*
|
2004-07-22 |
2007-10-23 |
Genentech Inc |
métodos de tratamento da sìndrome de sjÍgren e artigos manufaturados
|
WO2006041680A2
(en)
*
|
2004-10-05 |
2006-04-20 |
Genentech, Inc. |
Method for treating vasculitis
|
MY159370A
(en)
*
|
2004-10-20 |
2016-12-30 |
Coley Pharm Group Inc |
Semi-soft-class immunostimulatory oligonucleotides
|
EP1809671B1
(de)
*
|
2004-11-09 |
2014-07-16 |
University Of Southern California |
CpG/Antikörper Konjugat gegen Krebs
|
GT200600020A
(es)
*
|
2005-01-13 |
2006-11-08 |
|
Procedimiento de tratamiento
|
CN101137378A
(zh)
*
|
2005-01-20 |
2008-03-05 |
普罗热尼奇制药公司 |
甲基纳曲酮和相关化合物治疗术后胃肠功能障碍的用途
|
DOP2006000029A
(es)
*
|
2005-02-07 |
2006-08-15 |
Genentech Inc |
Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
|
US20060233791A1
(en)
*
|
2005-02-15 |
2006-10-19 |
Duke University |
Anti-CD19 antibodies and uses in oncology
|
US8444973B2
(en)
|
2005-02-15 |
2013-05-21 |
Duke University |
Anti-CD19 antibodies and uses in B cell disorders
|
JP2008531018A
(ja)
*
|
2005-02-24 |
2008-08-14 |
コーリー ファーマシューティカル グループ,インコーポレイテッド |
免疫刺激性オリゴヌクレオチド
|
PL1859793T3
(pl)
*
|
2005-02-28 |
2011-09-30 |
Eisai R&D Man Co Ltd |
Nowe połączone zastosowanie związku sulfonamidowego w leczeniu choroby nowotworowej
|
TW200714289A
(en)
*
|
2005-02-28 |
2007-04-16 |
Genentech Inc |
Treatment of bone disorders
|
US8518962B2
(en)
|
2005-03-07 |
2013-08-27 |
The University Of Chicago |
Use of opioid antagonists
|
US9662325B2
(en)
|
2005-03-07 |
2017-05-30 |
The University Of Chicago |
Use of opioid antagonists to attenuate endothelial cell proliferation and migration
|
US8524731B2
(en)
|
2005-03-07 |
2013-09-03 |
The University Of Chicago |
Use of opioid antagonists to attenuate endothelial cell proliferation and migration
|
MX2007010833A
(es)
*
|
2005-03-07 |
2009-02-17 |
Univ Chicago |
Uso de antagonistas opioides para atenuar proliferacion y migracion de células endoteliales.
|
JP2008535859A
(ja)
*
|
2005-04-08 |
2008-09-04 |
コーリー ファーマシューティカル グループ,インコーポレイテッド |
感染症によって悪化した喘息を治療するための方法
|
AR053579A1
(es)
*
|
2005-04-15 |
2007-05-09 |
Genentech Inc |
Tratamiento de la enfermedad inflamatoria intestinal (eii)
|
WO2006116458A2
(en)
*
|
2005-04-26 |
2006-11-02 |
Coley Pharmaceutical Gmbh |
Modified oligoribonucleotide analogs with enhances immunostimulatory activity
|
EP1885755A4
(de)
*
|
2005-05-05 |
2009-07-29 |
Univ Duke |
Cd19-antikörper-therapie für autoimmunerkrankungen
|
CN1865275B
(zh)
|
2005-05-17 |
2011-06-15 |
长春华普生物技术有限公司 |
对人b细胞肿瘤有治疗作用的人工合成的单链脱氧核苷酸
|
JP2008545958A
(ja)
*
|
2005-05-20 |
2008-12-18 |
ジェネンテック・インコーポレーテッド |
自己免疫性疾患の被検体の生体試料の前処理
|
AR057035A1
(es)
*
|
2005-05-25 |
2007-11-14 |
Progenics Pharm Inc |
SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
|
AR057325A1
(es)
*
|
2005-05-25 |
2007-11-28 |
Progenics Pharm Inc |
Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
|
US20080194611A1
(en)
*
|
2005-06-03 |
2008-08-14 |
Alverdy John C |
Modulation of Cell Barrier Dysfunction
|
ES2435531T3
(es)
*
|
2005-07-01 |
2013-12-20 |
Index Pharmaceuticals Ab |
Modulación de la capacidad de respuesta a los esteroides
|
PT2269622E
(pt)
|
2005-07-01 |
2014-03-20 |
Index Pharmaceuticals Ab |
Oligonucleotídeos cpg utilizados para aumentar a actividade dos esteróides num doente dependente de esteróides
|
US20090117132A1
(en)
*
|
2005-07-07 |
2009-05-07 |
Pfizer, Inc. |
Anti-Ctla-4 Antibody and Cpg-Motif-Containing Synthetic Oligodeoxynucleotide Combination Therapy for Cancer Treatment
|
US20080279850A1
(en)
*
|
2005-07-25 |
2008-11-13 |
Trubion Pharmaceuticals, Inc. |
B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
|
DK1912675T3
(en)
|
2005-07-25 |
2014-03-24 |
Emergent Product Dev Seattle |
B-cell reduction using specific and cd37-cd20-specific binding molecules
|
JP2009502936A
(ja)
|
2005-07-25 |
2009-01-29 |
トルビオン ファーマシューティカルズ, インコーポレイテッド |
Cd20特異的結合分子の単一投与量
|
US20090306177A1
(en)
*
|
2005-09-16 |
2009-12-10 |
Coley Pharmaceutical Gmbh |
Modulation of Immunostimulatory Properties of Short Interfering Ribonucleic Acid (Sirna) by Nucleotide Modification
|
WO2007088423A2
(en)
*
|
2005-09-16 |
2007-08-09 |
Coley Pharmaceutical Gmbh |
Immunostimulatory single-stranded ribonucleic acid with phosphodiester backbone
|
EP1940472A1
(de)
*
|
2005-10-28 |
2008-07-09 |
Index Pharmaceuticals AB |
Zusammensetzung und verfahren zur prävention, behandlung und/oder linderung einer entzündlichen erkrankung
|
GB0523041D0
(en)
*
|
2005-11-11 |
2005-12-21 |
Cyclacel Ltd |
Combination
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
CA2629306A1
(en)
*
|
2005-11-23 |
2007-05-31 |
Genentech, Inc. |
Methods and compositions related to b cell assays
|
KR20080072934A
(ko)
*
|
2005-11-25 |
2008-08-07 |
콜리 파마슈티칼 게엠베하 |
면역자극성 올리고리보뉴클레오티드
|
EP1991678B2
(de)
*
|
2006-02-15 |
2020-07-15 |
Rechtsanwalt Thomas Beck |
Zusammensetzungen und verfahren für oligonukleotidformulierungen
|
JP2009539413A
(ja)
*
|
2006-06-12 |
2009-11-19 |
トゥルビオン・ファーマシューティカルズ・インコーポレーテッド |
エフェクター機能を有する単鎖多価結合タンパク質
|
US20080031887A1
(en)
*
|
2006-06-30 |
2008-02-07 |
Joseph Lustgarten |
Conjugates for inducing targeted immune responses and methods of making and using same
|
AU2007280690C1
(en)
*
|
2006-07-31 |
2012-08-23 |
Curevac Gmbh |
Nucleic acid of formula (I): GIXmGn, or (II): CIXmCn, in particular as an immune-stimulating agent/adjuvant
|
DE102006035618A1
(de)
*
|
2006-07-31 |
2008-02-07 |
Curevac Gmbh |
Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
|
DK2383297T5
(da)
|
2006-08-14 |
2022-07-04 |
Xencor Inc |
Optimerede antistoffer rettet mod CD19
|
TW200817048A
(en)
*
|
2006-09-08 |
2008-04-16 |
Wyeth Corp |
Dry powder compound formulations and uses thereof
|
MX2009003398A
(es)
|
2006-09-27 |
2009-08-12 |
Coley Pharm Gmbh |
Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
|
US10925977B2
(en)
|
2006-10-05 |
2021-02-23 |
Ceil>Point, LLC |
Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
|
US20090142362A1
(en)
*
|
2006-11-06 |
2009-06-04 |
Avant Immunotherapeutics, Inc. |
Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP)
|
GB0625283D0
(en)
*
|
2006-12-19 |
2007-01-24 |
Cyclacel Ltd |
Combination
|
MX2009010552A
(es)
|
2007-03-29 |
2009-12-14 |
Progenics Pharm Inc |
Antagonistas de receptor de opioide periferico y usos de los mismos.
|
AU2008233133B2
(en)
|
2007-03-29 |
2014-03-27 |
Progenics Pharmaceuticals, Inc. |
Crystal forms of (R) -N-methylnaltrexone bromide and uses thereof
|
MX2009010515A
(es)
|
2007-03-29 |
2009-10-19 |
Wyeth Corp |
Antagonistas del receptor opioide periferico y usos de los mismos.
|
CN101687036A
(zh)
*
|
2007-04-27 |
2010-03-31 |
阿斯利康(瑞典)有限公司 |
治疗恶性血液病的chk1抑制剂与b细胞耗尽抗体
|
EP2573176B1
(de)
*
|
2007-05-04 |
2016-04-06 |
InDex Pharmaceuticals AB |
Tumorwachstumshemmende Verbindungen und Verfahren zu ihrer Verwendung
|
SI3597659T1
(sl)
|
2007-07-09 |
2023-04-28 |
Genentech, Inc. |
Preprečevanje redukcije disulfidne vezi med rekombinantno proizvodnjo polipeptidov
|
WO2009030254A1
(en)
|
2007-09-04 |
2009-03-12 |
Curevac Gmbh |
Complexes of rna and cationic peptides for transfection and for immunostimulation
|
AU2008298576A1
(en)
*
|
2007-09-13 |
2009-03-19 |
Molecular Insight Pharmaceuticals, Inc. |
Infusion and transfer system for use with radioactive agents
|
EP2200631A1
(de)
|
2007-10-16 |
2010-06-30 |
Zymogenetics, Inc. |
Kombination aus blys-hemmung und anti-cd20-wirkstoffen zur behandlung von autoimmunerkrankungen
|
EP2077281A1
(de)
|
2008-01-02 |
2009-07-08 |
Bergen Teknologioverforing AS |
Anti-CD20-Antikörper oder Fragmente davon zur Behandlung von chronischen Ermüdungssyndrom
|
CA2710534C
(en)
|
2008-01-31 |
2018-09-04 |
Curevac Gmbh |
Nucleic acids of formula (i) (nuglxmgnnv)a and derivatives thereof as an immunostimulating agent/adjuvant
|
KR101581480B1
(ko)
*
|
2008-02-06 |
2015-12-30 |
프로제닉스 파머슈티컬스, 인코포레이티드 |
(r),(r)-2,2'-비스-메틸날트렉손의 제조법 및 용도
|
CA2719134C
(en)
|
2008-03-21 |
2015-06-30 |
The University Of Chicago |
Treatment with opioid antagonists and mtor inhibitors
|
ES2368700T3
(es)
|
2008-04-11 |
2011-11-21 |
Emergent Product Development Seattle, Llc |
Agente inmunoterapéutico para cd37 y combinación con un agente quimioterapéutico bifuncional del mismo.
|
EP2300022A2
(de)
|
2008-04-25 |
2011-03-30 |
Duke University |
Regulierende b-zellen und ihre verwendungszwecke
|
EP2307002B1
(de)
|
2008-06-09 |
2013-01-02 |
Cyclacel Limited |
Kombinationen von sapacitabin oder cndac mit dna-methyltransferase-inhibitoren wie decitabin und procain
|
CA2728276A1
(en)
*
|
2008-06-18 |
2009-12-23 |
Index Pharmaceuticals Ab |
Combination therapies against cancer
|
TWI351288B
(en)
*
|
2008-07-04 |
2011-11-01 |
Univ Nat Pingtung Sci & Tech |
Cpg dna adjuvant in avian vaccines
|
NZ591130A
(en)
*
|
2008-08-25 |
2012-09-28 |
Amplimmune Inc |
Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof
|
TW201014605A
(en)
|
2008-09-16 |
2010-04-16 |
Genentech Inc |
Methods for treating progressive multiple sclerosis
|
CA2676881C
(en)
|
2008-09-30 |
2017-04-25 |
Wyeth |
Peripheral opioid receptor antagonists and uses thereof
|
WO2010037408A1
(en)
|
2008-09-30 |
2010-04-08 |
Curevac Gmbh |
Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
|
WO2010053433A1
(en)
*
|
2008-11-04 |
2010-05-14 |
Index Pharmaceuticals Ab |
Increased expression of specific antigens
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
CA3033133C
(en)
|
2009-03-25 |
2021-11-09 |
The Board Of Regents Of The University Of Texas System |
Compositions for stimulation of mammalian innate immune resistance to pathogens
|
WO2010132622A2
(en)
*
|
2009-05-14 |
2010-11-18 |
The Regents Of The University Of California |
Anticd20-cpg conjugates and methods of treating b cell malignancies
|
HUE048980T2
(hu)
|
2009-08-11 |
2020-08-28 |
Hoffmann La Roche |
Fehérjék elõállítása glutaminmentes sejttenyésztõ táptalajban
|
US20110053829A1
(en)
|
2009-09-03 |
2011-03-03 |
Curevac Gmbh |
Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
|
CN102933231B
(zh)
|
2010-02-10 |
2015-07-29 |
伊缪诺金公司 |
Cd20抗体及其用途
|
US20130224237A1
(en)
*
|
2010-07-20 |
2013-08-29 |
University Of Miami |
Inhibition of nonsense mediated decay pathways
|
EP2449113B8
(de)
|
2010-07-30 |
2015-11-25 |
CureVac AG |
Komplexierung von nucleinsäuren mit disulfid-vernetzten kationischen bestandteilen zur transfektion und immunstimulation
|
EP2600878A4
(de)
|
2010-08-04 |
2014-06-11 |
Univ Duke |
Regulatorische b-zellen und ihre verwendungen
|
WO2012064671A1
(en)
*
|
2010-11-08 |
2012-05-18 |
The Ohio State University Research Foundation |
Compositions and methods for increasing drug efficacy in cancer
|
US9814740B2
(en)
*
|
2010-12-21 |
2017-11-14 |
Duke University |
Methods and compositions combining immunotherapy with monocyte activation
|
JP5930146B2
(ja)
*
|
2011-03-28 |
2016-06-08 |
国立研究開発法人物質・材料研究機構 |
免疫刺激オリゴヌクレオチドおよび前記免疫刺激オリゴヌクレオチドを含む治療剤
|
PL2696878T3
(pl)
|
2011-04-14 |
2020-01-31 |
Cyclacel Limited |
Schemat dawkowania dla sapacytabiny i decytabiny w kombinacji do leczenia ostrej białaczki szpikowej
|
US20130157261A1
(en)
*
|
2011-06-01 |
2013-06-20 |
The Methodist Hospital Research Institute |
Compositions and Methods for Quantitative Histology, Calibration of Images in Fluorescence Microscopy, and ddTUNEL Analyses
|
WO2013113326A1
(en)
|
2012-01-31 |
2013-08-08 |
Curevac Gmbh |
Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
|
US10017739B2
(en)
|
2012-09-06 |
2018-07-10 |
Duke University |
Methods of expanding and assessing B cells and using expanded B cells to treat disease
|
JP6896421B2
(ja)
|
2013-08-21 |
2021-06-30 |
キュアバック アーゲー |
呼吸器合胞体ウイルス(rsv)ワクチン
|
US10436680B2
(en)
|
2013-10-15 |
2019-10-08 |
Kianoosh Peyvan |
Capture, disruption, and extraction apparatus and method
|
EP3096787A4
(de)
*
|
2014-01-22 |
2018-02-07 |
The Board of Trustees of the Leland Stanford Junior University |
Verfahren und zusammensetzungen für antikörper- und antikörpergeladene dendritische zellvermittelte therapie
|
CA2936286A1
(en)
|
2014-04-01 |
2015-10-08 |
Curevac Ag |
Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
|
US10286065B2
(en)
|
2014-09-19 |
2019-05-14 |
Board Of Regents, The University Of Texas System |
Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
|
EP3352760A4
(de)
|
2015-09-21 |
2019-03-06 |
Aptevo Research and Development LLC |
Cd3-bindende polypeptide
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
CN114014936A
(zh)
|
2015-10-02 |
2022-02-08 |
豪夫迈·罗氏有限公司 |
双特异性抗人cd20/人转铁蛋白受体抗体及使用方法
|
WO2017070133A1
(en)
*
|
2015-10-20 |
2017-04-27 |
Sorrento Therapeutics, Inc. |
Intracellular delivery compounds
|
WO2017192959A2
(en)
*
|
2016-05-05 |
2017-11-09 |
The Research Foundation For The State University Of New York |
Therapeutically modulating apob and apoai
|
CN115317603A
(zh)
|
2016-07-07 |
2022-11-11 |
小利兰·斯坦福大学托管委员会 |
抗体佐剂缀合物
|
CN110248668B
(zh)
|
2016-12-15 |
2023-05-30 |
杜克大学 |
用于消耗调节性b10细胞的抗体和方法以及与免疫检查点抑制剂的联用
|
NZ758119A
(en)
|
2017-04-14 |
2024-03-22 |
Tallac Therapeutics Inc |
Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
|
WO2020190725A1
(en)
|
2019-03-15 |
2020-09-24 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates targeting her2
|
CN111826764B
(zh)
*
|
2020-07-28 |
2021-10-15 |
吴忠德悦纺织科技有限公司 |
一种改性多组份复合纱线的制备方法
|
CN114216985A
(zh)
*
|
2021-12-22 |
2022-03-22 |
珠海润都制药股份有限公司 |
一种异山梨醇中硫酸二异丙酯的检验方法
|